loading
전일 마감가:
$15.95
열려 있는:
$16.06
하루 거래량:
2.61M
Relative Volume:
2.07
시가총액:
$1.32B
수익:
$139.71M
순이익/손실:
$-209.36M
주가수익비율:
-6.0659
EPS:
-2.58
순현금흐름:
$-160.60M
1주 성능:
-6.79%
1개월 성능:
-19.87%
6개월 성능:
-24.25%
1년 성능:
+2.09%
1일 변동 폭
Value
$15.00
$16.27
1주일 범위
Value
$15.00
$16.91
52주 변동 폭
Value
$15.00
$25.34

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name
명칭
Syndax Pharmaceuticals Inc
Name
전화
781-419-1400
Name
주소
35 GATEHOUSE DRIVE, WALTHAM, MA
Name
직원
184
Name
트위터
@syndax
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
SNDX's Discussions on Twitter

SNDX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
SNDX 15.65 1.32B 139.71M -209.36M -160.60M -2.58
VRTX 450.13 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.09 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 597.50 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.26 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.24 24.89B 3.30B -501.07M 1.03B 11.54

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-01-31 다운그레이드 Scotiabank Sector Outperform → Sector Perform
2023-12-22 개시 Mizuho Buy
2023-10-25 개시 BofA Securities Buy
2023-10-11 개시 Goldman Buy
2023-07-27 개시 Scotiabank Sector Outperform
2023-07-11 개시 Guggenheim Buy
2023-04-17 재개 BTIG Research Buy
2023-01-31 개시 Stifel Buy
2023-01-03 개시 JP Morgan Overweight
2022-07-28 재개 B. Riley Securities Buy
2022-04-11 개시 H.C. Wainwright Buy
2022-02-15 개시 Goldman Buy
2021-06-04 재개 Robert W. Baird Outperform
2021-05-25 개시 Citigroup Buy
2021-02-18 개시 B. Riley Securities Buy
2020-12-03 개시 Stifel Buy
2020-05-22 업그레이드 Citigroup Neutral → Buy
2020-05-22 다운그레이드 H.C. Wainwright Buy → Neutral
2020-05-18 다운그레이드 Citigroup Buy → Neutral
2020-05-11 재확인 H.C. Wainwright Buy
2020-03-04 개시 Barclays Overweight
2020-01-13 재확인 H.C. Wainwright Buy
2019-03-08 재확인 H.C. Wainwright Buy
2019-01-04 개시 Robert W. Baird Outperform
2018-01-05 개시 B. Riley FBR, Inc. Buy
2017-03-16 개시 FBR & Co. Outperform
2017-03-02 개시 Instinet Buy
2016-10-07 개시 Guggenheim Buy
2016-03-28 개시 Citigroup Buy
2016-03-28 개시 JMP Securities Mkt Outperform
2016-03-28 개시 Morgan Stanley Overweight
모두보기

Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스

pulisher
08:05 AM

Kura Signs Leukemia Pact with Kyowa Kirin After Losing Race to Syndax - BioSpace

08:05 AM
pulisher
02:30 AM

Citigroup Boosts Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $45.00 - Defense World

02:30 AM
pulisher
01:52 AM

What is B. Riley’s Forecast for SNDX FY2024 Earnings? - Defense World

01:52 AM
pulisher
01:49 AM

HC Wainwright Brokers Increase Earnings Estimates for SNDX - Defense World

01:49 AM
pulisher
Nov 20, 2024

Jefferies Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy Recommendation - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

FY2024 Earnings Estimate for SNDX Issued By HC Wainwright - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

B. Riley Has Bullish Outlook for SNDX FY2024 Earnings - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

HC Wainwright Forecasts Strong Price Appreciation for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - Defense World

Nov 20, 2024
pulisher
Nov 19, 2024

Citigroup Raises Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $45.00 - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

First Turn Management LLC Raises Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval - MedCity News

Nov 18, 2024
pulisher
Nov 18, 2024

Syndax Scores First-Mover Advantage With Approval Of Menin Inhibitor For Leukemia - Citeline News & Insights

Nov 18, 2024
pulisher
Nov 18, 2024

Syndax secures FDA OK for new kind of leukemia drug - BioPharma Dive

Nov 18, 2024
pulisher
Nov 18, 2024

First Week of July 2025 Options Trading For Syndax Pharmaceuticals (SNDX) - Nasdaq

Nov 18, 2024
pulisher
Nov 18, 2024

HC Wainwright Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

FDA approves Syndax’s Revuforj to treat leukaemia - Yahoo Finance

Nov 18, 2024
pulisher
Nov 18, 2024

Syndax gets FDA okay for first-in-class leukaemia drug - pharmaphorum

Nov 18, 2024
pulisher
Nov 17, 2024

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Upgraded by StockNews.com - Defense World

Nov 17, 2024
pulisher
Nov 17, 2024

Syndax Pharmaceuticals (NASDAQ:SNDX) Raised to Hold at StockNews.com - MarketBeat

Nov 17, 2024
pulisher
Nov 15, 2024

US FDA approves Syndax's blood cancer drug - Reuters.com

Nov 15, 2024
pulisher
Nov 15, 2024

Syndax's Revuforj Wins FDA Approval as First Menin Inhibitor for Acute Leukemia | SNDX Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 15, 2024

Simplify Asset Management Inc. Buys 46,992 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

(SNDX) Investment Analysis and Advice - Stock Traders Daily

Nov 15, 2024
pulisher
Nov 14, 2024

Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid FDA approvals By Investing.com - Investing.com South Africa

Nov 14, 2024
pulisher
Nov 14, 2024

Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint - Pharmaceutical Technology

Nov 14, 2024
pulisher
Nov 13, 2024

Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid FDA approvals - Investing.com UK

Nov 13, 2024
pulisher
Nov 13, 2024

Syndax’s revumenib meets primary results in AML trial - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Syndax shares slide despite pivotal trial success - The Pharma Letter

Nov 13, 2024
pulisher
Nov 12, 2024

Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity (NASDAQ:SNDX) - Seeking Alpha

Nov 12, 2024
pulisher
Nov 12, 2024

Syndax Pharmaceuticals Inc Still Hasn’t Convinced Analysts? - Stocks Register

Nov 12, 2024
pulisher
Nov 12, 2024

Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL

Nov 12, 2024
pulisher
Nov 12, 2024

Syndax falls after mid-stage data for leukemia drug - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Syndax stock falls after leukemia drug data (SNDX:NASDAQ) - Seeking Alpha

Nov 12, 2024
pulisher
Nov 12, 2024

Syndax's Revumenib Trial Hits Key Endpoint with 47% Response Rate in AML Treatment | SNDX Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 10, 2024

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $47.00 Price Target at HC Wainwright - Defense World

Nov 10, 2024
pulisher
Nov 09, 2024

Creative Planning Has $318,000 Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Nov 09, 2024
pulisher
Nov 09, 2024

HC Wainwright Analysts Increase Earnings Estimates for SNDX - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

Wellington Management Group LLP's Strategic Reduction in Syndax Pharmaceuticals Inc - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

HC Wainwright Has Bullish Outlook for SNDX FY2024 Earnings - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Nov 08, 2024
pulisher
Nov 08, 2024

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

The Goldman Sachs Group Forecasts Strong Price Appreciation for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024
pulisher
Nov 06, 2024

Earnings call: Syndax Pharmaceuticals outlines Q3 2024 progress By Investing.com - Investing.com Canada

Nov 06, 2024
pulisher
Nov 06, 2024

Syndax and Royalty Pharma finalize $350 million deal | Pharmaceutical | The Pharmaletter - The Pharma Letter

Nov 06, 2024
pulisher
Nov 06, 2024

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highligh - GuruFocus.com

Nov 06, 2024
pulisher
Nov 05, 2024

Syndax Pharmaceuticals: Key Pipeline Developments and Financial Update - TipRanks

Nov 05, 2024

Syndax Pharmaceuticals Inc (SNDX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
자본화:     |  볼륨(24시간):